Clear Investment Research LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Lindsey Winhoffer on May 26th, 2023

Clear Investment Research LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,215 shares of the company’s stock after buying an additional 72 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of Clear Investment Research LLC’s investment portfolio, making the stock its 26th biggest holding. Clear Investment Research LLC’s holdings in Johnson & Johnson were worth $391,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter valued at $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson during the third quarter valued at $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $52,000. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JNJ shares. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Trading Down 1.4 %

Johnson & Johnson stock opened at $154.41 on Friday. The firm’s 50-day moving average is $159.89 and its 200-day moving average is $165.86. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The company has a market cap of $401.27 billion, a P/E ratio of 32.30, a PEG ratio of 2.67 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $2.67 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.08%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.